Objective To compare the effects of treatments for coronavirus disease 2019 (covid-19).
Design Living systematic review and network meta-analysis. Data sources WHO covid-19 …

Background Randomized controlled trials (RCT) established the mortality reduction by
tocilizumab (Actemra), baricitinib (Olumiant), and sarilumab (Kevzara) in hospitalized COVID …

Inflammation is a complex pathophysiological process underlying many clinical conditions.
Platelets contribute to the thrombo‐inflammatory response. Platelet P2Y12 receptors amplify …

Tocilizumab is an interleukin (IL)‐6 receptor inhibitor that has been proposed as a
therapeutic agent for treating coronavirus disease 2019 (COVID‐19). The aim of this …

Background A recent prospective meta-analysis demonstrated that interleukin-6 antagonists
are associated with lower all-cause mortality in hospitalised patients with COVID-19 …

The COVID-19 pandemic has been at the forefront of medicine over the last few years.
Pregnant women are often exposed to infectious agents that can be harmful not only to the …

Inflammation can trigger lasting phenotypes in immune and non-immune cells. Whether and
how human infections and associated inflammation can form innate immune memory in …

Objective The aim of this study is to explore the role of IL6 in predicting outcome in critically
ill COVID-19 patients. Design Prospective observational cohort study. Setting 20-bed …

Abstract Background The SARS‐CoV‐2 pandemic has spurred an unparalleled scientific
endeavor to elucidate the virus' structure, infection mechanisms, and pathogenesis. Two …

In 2019, a new disease called Covid-19 was detected in Wuhan located in China which
caused seriously disease or death at any age. This disease has various symptoms such as …